Wikipedia

N-Phenylacetyl-L-prolylglycine ethyl ester

N-Phenylacetyl-l-prolylglycine ethyl ester is promoted as a nootropic and is a prodrug of cyclic glycine-proline.[a][2] Other names include the brand name Noopept (Russian: Ноопепт), developmental code GVS-111, and proposed INN omberacetam.[2][3][4]

N-Phenylacetyl-L-prolylglycine ethyl ester
Clinical data
Trade namesNoopept
Other namesomberacetam; GVS-111; DVD-111; SGS-111; benzylcarbonyl-Pro-Gly-OEt
Legal status
Legal status
  • AU: S4 (Prescription only)
  • US: Unapproved "New Drug" (as defined by 21 U.S. Code § 321(p)(1)). Use in dietary supplements, food, or medicine is unlawful; otherwise uncontrolled.
Identifiers
  • Ethyl 1-(phenylacetyl)-l-prolylglycinate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H22N2O4
Molar mass318.373 g·mol−1
3D model (JSmol)
  • c2ccccc2CC(=O)N1CCC[C@@H]1C(=O)NCC(=O)OCC
  • InChI=1S/C17H22N2O4/c1-2-23-16(21)12-18-17(22)14-9-6-10-19(14)15(20)11-13-7-4-3-5-8-13/h3-5,7-8,14H,2,6,9-12H2,1H3,(H,18,22)/t14-/m0/s1 ☒N
  • Key:PJNSMUBMSNAEEN-AWEZNQCLSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Its synthesis was first reported in 1996.[2] It is orally available. As of 2017, its metabolism and elimination half-life in humans were not well understood.[2]

It has been evaluated for neuroprotective effects in treating brain injuries and stroke.[5]

Pharmacology

edit

One oft-cited study (originally published in Russian) conducted on rats, suggests that Noopept works via the "antioxidant effect, the anti-inflammatory action, and the ability to inhibit the neurotoxicity of excess calcium and glutamate, and to improve the blood rheology".[5] Studies in rats suggest, Noopept is a prodrug of the endogenous dipeptide cycloprolylglycine.[6] Cycloprolylglycine is a modulator of AMPA receptors and exerts neuroprotective effects dependent upon AMPA- and TrkB-Receptor activation.[7] In cell culture, cycloprolylglycine increases brain derived neurotrophic factor (BDNF).[8]

Some studies suggest that the pharmacological properties of Noopept are derived from its action as an activator of Hypoxia-inducible factor (HIF-1).[9][10]

Dosage

edit

Noopept is frequently dosed at 10–30 mg per day. However, there is no solid evidence indicating that any dose of Noopept is optimal. Few human trials have ever been carried out on Noopept, and as one meta-analysis notes, animal studies have used doses ranging from 0.1 mg/kg bodyweight to 10 mg/kg bodyweight.[unreliable medical source?][11] Furthermore, no long-term studies have been done to evaluate the lasting effects of chronic use at any given dose; the longest human study lasted for 56 days.[12] There is, therefore, no dose of Noopept which may be called "safe".

edit
  • Hungary: As of 25 August 2020, Noopept is added to the controlled psychoactive substances list, prohibiting production, sale, import, storage and use.[13]
  • Russia: Noopept in Russia is a drug of medicine and is available without a prescription.[14]
  • United Kingdom: Contrary to popular belief, omberacetam is not illegal to produce, supply, or import under the Psychoactive Substance Act in the UK, which came into effect on May 26, 2016 because it neither works as a CNS (central nervous system) depressant, nor as a CNS stimulant.[15] However, sale and supply for human consumption are prohibited.
  • United States: The Food and Drug Administration has issued import alerts for imports of omberacetam, considering it an analog of piracetam.[16] FDA considers such racetam-family substances Active Pharmaceutical Ingredients (APIs) that require new drug applications and adequate labelling before being imported.[17] Similarly, warnings have been issued for claims of medical and pharmacological effects.[18] Despite these FDA enforcement actions, omberacetam is sold in over-the-counter supplements in the US, with some products formulated with dosages greater than pharmaceutical levels.[19]

See also

edit

Notes

edit
  1. ^ Referring to the cyclic dipeptide better known as cyclo(prolylglycyl), i.e. (S)-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione.[1] Not to be confused with a cyclopropanyl moiety.

References

edit
  1. ^ "Omberacetam". Inxight. National Center for Advancing Translational Sciences (NCATS). 4QBJ98683M.
  2. ^ a b c d "Noopept Information". Examine.com. Retrieved 6 April 2017.
  3. ^ "Proposed INN List 117". WHO Drug Information. 31 (2): 308. 2017.
  4. ^ "Omberacetam". AdisInsight. Springer Nature Switzerland AG. Retrieved 12 May 2018. Alternative Names: DVD-111; GVS 111; Noopept
  5. ^ a b Ostrovskaia RU, Gudasheva TA, Voronina TA, Seredenin SB (2002). "[The original novel nootropic and neuroprotective agent noopept]" [The original novel nootropic and neuroprotective agent noopept]. Eksperimental'naia i Klinicheskaia Farmakologiia [Experimental and Clinical Pharmacology] (in Russian). 65 (5): 66–72. PMID 12596521.
  6. ^ Gudasheva TA, Boyko SS, Ostrovskaya RU, Voronina TA, Akparov VK, Trofimov SS, et al. (1997). "The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine". European Journal of Drug Metabolism and Pharmacokinetics. 22 (3): 245–252. doi:10.1007/BF03189814. PMID 9358206.
  7. ^ Gudasheva TA, Koliasnikova KN, Alyaeva AG, Nikolaev SV, Antipova TA, Seredenin SB (December 2022). "Neuroprotective Effect of the Neuropeptide Cycloprolylglycine Depends on AMPA- and TrkB-Receptor Activation". Doklady. Biochemistry and Biophysics. 507 (1): 264–267. doi:10.1134/S1607672922060047. PMID 36786983.
  8. ^ Gudasheva TA, Koliasnikova KN, Antipova TA, Seredenin SB (July 2016). "Neuropeptide cycloprolylglycine increases the levels of brain-derived neurotrophic factor in neuronal cells". Doklady. Biochemistry and Biophysics. 469 (1): 273–276. doi:10.1134/S1607672916040104. PMID 27599510. S2CID 254426990.
  9. ^ Zainullina LF, Ivanova TV, Sadovnikov SV, Vakhitova YV, Seredenin SB (September 2020). "Cognitive Enhancer Noopept Activates Transcription Factor HIF-1". Doklady. Biochemistry and Biophysics. 494 (1): 256–260. doi:10.1134/S1607672920050129. PMID 33119829. S2CID 226207175.
  10. ^ Vakhitova YV, Sadovnikov SV, Borisevich SS, Ostrovskaya RU, A Gudasheva T, Seredenin SB (2016). "Molecular Mechanism Underlying the Action of Substituted Pro-Gly Dipeptide Noopept". Acta Naturae. 8 (1): 82–89. doi:10.32607/20758251-2016-8-1-82-89. PMC 4837574. PMID 27099787.
  11. ^ Tardner P (2020). "Finding the optimal dosage fornootropic agent Noopept: An analysis of available literature" (PDF). International Journal of Environmental Science and Technology.
  12. ^ Neznamov GG, Teleshova ES (March 2009). "Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin". Neuroscience and Behavioral Physiology. 39 (3): 311–321. doi:10.1007/s11055-009-9128-4. PMID 19234797. S2CID 3348153.
  13. ^ Miklós K (25 August 2020). "Az új pszichoaktív anyaggá minősített anyagokról vagy vegyületcsoportokról szóló 55/2014. (XII. 30.) EMMI rendelet módosításáról" [About substances classified as new psychoactive substances or 55/2014 on groups of compounds (XII. 30.) amending the EMMI Decree]. Magyarország Hivatalos Lapja [Official Journal of Hungry] (in Hungarian). 194: 6135–6142 (6139). Retrieved 28 April 2021.
  14. ^ "Ноопепт" [Noopept]. Государственный реестр лекарственных средств [State Register of Medicines] (in Russian).
  15. ^ "Psychoactive Substances Act 2016". Legislation.gov.uk.
  16. ^ Cohen PA, Zakharevich I, Gerona R (March 2020). "Presence of Piracetam in Cognitive Enhancement Dietary Supplements". JAMA Internal Medicine. 180 (3): 458–459. doi:10.1001/jamainternmed.2019.5507. PMC 6902196. PMID 31764936.
  17. ^ "Import alert 66-66". U.S. Food and Drug Administration. 7 September 2021.
  18. ^ Correll Jr WA (5 February 2019). "Peak Nootropics LLC aka Advanced Nootropics". FDA Warning letter. U.S. Food and Drug Administration.
  19. ^ Cohen PA, Avula B, Wang YH, Zakharevich I, Khan I (June 2021). "Five Unapproved Drugs Found in Cognitive Enhancement Supplements". Neurology. Clinical Practice. 11 (3): e303–e307. doi:10.1212/CPJ.0000000000000960. PMC 8382366. PMID 34484905.
Retrieved from "https://en.wikipedia.org/w/index.php?title=N-Phenylacetyl-L-prolylglycine_ethyl_ester&oldid=1254094856"